A federal appeals court has upheld the dismissal of a whistleblower's claims against Heritage Operations Group, LLC, and Green Tree Pharmacy, Inc. A. Samuel Enloe alleged that the two companies committed fraud by submitting false claims to Medicare. The court's decision, issued on August 17, 2026, is significant for those involved in healthcare compliance and fraud prevention.
The case stems from allegations that Heritage, which operates long-term care facilities in Illinois, and Green Tree, which provides pharmacy services to these facilities, dispensed controlled substances without proper pharmacist approval. Enloe claimed these actions violated the False Claims Act (FCA) and the Controlled Substances Act (CSA). The court's ruling clarifies the standards for proving fraud in healthcare settings.
Enloe, a former employee in the long-term care pharmacy industry, accused Heritage and Green Tree of dispensing Schedule II drugs, such as opioids, without valid prescriptions. He argued that the companies submitted claims to Medicare for reimbursement based on these illegal prescriptions. Enloe's allegations were based on an internal policy from Green Tree regarding emergency narcotics kits, which outlined how and when medications could be dispensed.
The dispute reached the Court of Appeals for the Seventh Circuit after the district court dismissed Enloe's second amended complaint. The district court found that Enloe failed to provide sufficient details about the alleged fraud, as required by the Federal Rules of Civil Procedure. Enloe appealed this decision, seeking to reinstate his claims.
The Seventh Circuit, led by Judge Maldonado, reviewed the case and ultimately affirmed the lower court's ruling. The court found that Enloe did not meet the heightened pleading requirements for fraud under the FCA. The opinion stated, "Enloe’s allegations amount to speculation resting on layers of assumptions unsupported by any concrete factual allegations."
The court emphasized that to succeed under the FCA, a plaintiff must show that the defendant knowingly presented false claims for payment to the government. The court noted that Enloe's claims did not rise to this level, as they were based on vague regulations and did not provide a clear factual basis for the alleged fraud.
The ruling also addressed Enloe's claims regarding the CSA, concluding that the Act does not provide a private cause of action for individuals to sue. As a result, the court dismissed Enloe's claims under both the FCA and the CSA, as well as his claim for unjust enrichment.
This decision has important implications for whistleblowers and healthcare providers. It underscores the necessity for clear and specific allegations when bringing fraud claims under the FCA. The court's ruling highlights the challenges that whistleblowers face, particularly when they do not have direct access to the alleged fraudulent activities.
Looking ahead, this ruling may discourage similar claims unless whistleblowers can present more concrete evidence of wrongdoing. The decision reinforces the legal standards that must be met to establish fraud in healthcare settings, particularly regarding compliance with Medicare regulations.
As of now, it is unclear if Enloe will seek to appeal the ruling to the U.S. Supreme Court or if there are any related cases pending that may influence future litigation in this area. The court's decision serves as a reminder of the complexities involved in proving fraud and the importance of compliance in the healthcare industry.